Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging

Wong, Ching Yee Oliver; Qian, Feng; Savin, Michael A.; Campbell, Janice; Gates, Vanessa L.; Sherpa, Kanchi M.; Lewandowski, Robert J.; Nagle, Cate; Salem, Riad

doi:10.1097/01.rvi.0000168104.32849.07

Cited by 79 publications

(42 citation statements)

References 20 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our opinion the effect on the overall volume of the lobe is only minor. Wong et al proved in multiple studies that lesion size alone might underestimate any treatment effect [41][42][43][44]. The authors described a superior metabolic response proven by positron emission tomography (PET) after 90 yttrium than by lesion size.…”

Section: Discussionmentioning

confidence: 97%

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In a significant number of cases 'stable disease' could actually be minor, partial, or even complete response. In order to improve sensitivity in assessing tumor response, it is therefore strongly recommended that 18 F-FDG-PET or functional MRI (diffusion-weighted MRI) is added to posttreatment response assessment protocols [56][57][58][59].…”

Section: Discussionmentioning

confidence: 99%

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

et al. 2008

View full text Add to dashboard Cite

“…19,21,[26][27][28][29] Similar to previous findings, the PET response rate in our study was 77%. [30][31][32][33][34] Outcomes in this report are described from the date of diagnosis of CRC to account for differences in survival among patients who presented with stage II or III disease compared with patients who presented with stage IV disease. Survival from the date of hepatic metastases describes the outcome when Y90 is incorporated into the continuum of care, regardless of the line of therapy, and explores the influence of Y90 therapy on previous or subsequent systemic therapy.…”

Section: Discussionmentioning

confidence: 99%

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Mulcahy

Lewandowski

Ibrahim

et al. 2009

Cancer

Self Cite

156

View full text Add to dashboard Cite

BACKGROUND:The objective of the current study was to determine the safety and efficacy of Yttrium‐90 (Y90) microsphere treatment in patients with liver‐dominant colorectal metastases.METHODS:Seventy‐two patients with unresectable hepatic colorectal metastases were treated at a targeted absorbed dose of 120 Gray (Gy). Safety and toxicity were assessed using version 3 of the National Cancer Institute Common Terminology Criteria. Response was assessed by anatomic imaging and positron emission tomography (PET). Survival from the diagnosis of hepatic metastases and first treatment were estimated using the Kaplan‐Meier method. Substratification analyses were performed.RESULTS:The median dose delivered was 118 Gy. Treatment‐related toxicities included fatigue (61%), nausea (21%), and abdominal pain (25%). Grade 3 and 4 bilirubin toxicities were observed in 9 of 72 patients (12.6%). The tumor response rate was 40.3%. The median time to hepatic progression was 15.4 months, and the median response duration was 15 months. The PET response rate was 77%. Overall survival from the first Y90 treatment was 14.5 months. Tumor replacement (≤25% vs >25%) was associated with significantly greater median survival (18.7 months vs 5.2 months). The presence of extrahepatic disease was associated negatively with overall survival (7.9 months vs 21 months). Overall survival from the date of initial hepatic metastases was 34.6 months. A subset analysis of patients who had an Eastern Cooperative Oncology Group performance status of 0 demonstrated a median survival of 42.8 months and 23.5 months from the time of hepatic metastases and Y90 treatment, respectively.CONCLUSIONS:Y90 liver therapy appears to provide sustained disease stabilization with acceptable toxicity. Asymptomatic patients with preserved liver function at the time of Y90 appeared to benefit most from treatment. Cancer 2009. © 2009 American Cancer Society.

show abstract

Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging

Cited by 79 publications

References 20 publications

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres

Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis

Radioembolization of colorectal hepatic metastases using yttrium‐90 microspheres

Contact Info

Product

Resources

About